Curcumin’s Effect оn COX-2 аnd IL-10 Serum in Preeclampsia’s Patient Undergo Sectio Caesarea with Spinal Anesthesia

Abstract

BACKGROUND: Curcumin is a major component in curcuminoid which acts as an anti-inflammatory agent. Curcumin affects several biological markers that are thought to play a role in the pathogenesis of preeclampsia such as IL-10 and COX-2, resulting in an improvement in pregnant women with preeclampsia.
 AIM: To see the effect of perioperative curcumin administration on IL-10 and COX-2 in preeclamptic patients undergoing caesarean section under spinal anaesthesia.
 METHODS: This study was a double-blind, randomised clinical trial conducted at Pirngadi Hospital, USU Hospital and Sundari General Hospital Medan as a hospital network of Faculty of Medicine, North Sumatra University. Group 1 received a drug containing curcumin (as a treatment), and another group received a placebo (as a control).
 RESULTS: There were no significant differences in the median values of COX-2 and IL-10 before and after treatment and also the p-values were greater than 0.05 in both groups (control and treatment).
 CONCLUSION: There is no significant difference between the use of curcumin on serum COX-2 and IL-10 levels.

Curcumin: Could This Compound Be Useful in Pregnancy and Pregnancy-Related Complications?

“…Recently, a double-blind randomized clinical trial involving 47 pregnant women with preeclampsia was conducted to evaluate the possible effect of curcumin on the expression of COX-2 and IL-10, thought to have a role in the pathogenesis of PE. The enrolled patients were randomized to receive either curcumin 100 mg/d ( n = 23) or placebo ( n = 24) [ 54 ]. The authors analyzed the circulating levels of IL-10 and COX-2, at T0, 90 min after curcumin ingestion, and 12 h after delivery.…”

“…Results showed that curcumin did not modify the expression of the analyzed molecules at any tested time. The authors hypothesized that the absence of effect might be due to the low dose of curcumin, taking into account that in non-pregnant subjects doses can reach more than 1 g/day [ 54 ].…”

Plant Phenolics and Extracts in Animal Models of Preeclampsia and Clinical Trials—Review of Perspectives for Novel Therapies

“…-no significant differences in level of markers in serum of patients. [91] Epigallocatechin gallate -double-blind, randomized, placebo-controlled clinical trial, -pregnant women with severe pre-eclampsia (n = 304 patients), -dose of epigallocatechin gallate:…”

“…Fadinie et al [ 91 ] drew attention to the anti-inflammatory properties of curcumin, which can inhibit the activation of NF-κβ and may influence the activity and concentrations of COX-2 and IL-10, involved in the pathogenesis of preeclampsia. In order to verify this assumption, Fadinie et al [ 91 ] carried out a double-blinded, randomized clinical trial with pregnant women with preeclampsia ( n = 47). Patients received medicinal products containing 100 mg of curcumin once daily ( n = 23).…”

“… - no significant differences in level of markers in serum of patients. [ 91 ] Epigallocatechin gallate - double-blind, randomized, placebo-controlled clinical trial, - pregnant women with severe pre-eclampsia ( n = 304 patients), - dose of epigallocatechin gallate: (1) 100 mg with 10 mg nifedipine, (2) 100 mg without nifedipine. - more effective of the combination of two drugs in therapy, - reducing time needed to control blood pressure after combinational treatment, - lower number of treatment doses needed to control blood pressure after combinational treatment, - decreasing the side effects of nifedipine, i.e., vomiting and hypotension after epigallocatechin gallate.…”